Artwork

المحتوى المقدم من Nutraceuticals World. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Nutraceuticals World أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !

NAD+ and Aging: ChromaDex CEO Rob Fried Discusses Science, Industry Challenges and Future Expectations

40:53
 
مشاركة
 

Manage episode 408275212 series 2805304
المحتوى المقدم من Nutraceuticals World. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Nutraceuticals World أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

With rising interest in healthy aging, more people are looking for clinical research that supports products designed to help them live healthier for longer.
The coenzyme NAD+ is essential to the body's metabolic processes, but it declines with age, so supplements that boost NAD+ have garnered considerable attention in the scientific community.
ChromaDex, which is publicly traded on the Nasdaq, offers the consumer product brand Tru Niagen. This patented form of nicotinamide riboside (NR) is a precursor to NAD+.
Tru Niagen sales totaled nearly $70 million last year, accounting for the majority of the company’s $83.6 million in revenue.
In this interview, ChromaDex CEO Rob Fried discusses NAD+ and emerging research, the company’s evolution to become a consumer-focused nutraceutical, the future of aging, critical challenges in today’s dietary supplement market, and more.
Spoiler alert: Fried is calling for more accountability and collaboration to enforce quality standards and establish greater trust with consumers.
In addition to being CEO of ChromaDex since 2017 and the founder of Tru Niagen, Fried is an Academy Award and Emmy Award winning motion picture producer. Before his combined 7 years in the health industry, he held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President) and Fried Films (founder, CEO). He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research LLC.
In 2017, Fried led ChromaDex’s acquisition of Healthspan Research LLC, a consumer company offering Tru Niagen products, and raised funds with Horizon Ventures to offer Tru Niagen direct-to-consumer. He holds a BS from Cornell University and an MBA from the Columbia University Graduate School of Business.

  continue reading

24 حلقات

Artwork
iconمشاركة
 
Manage episode 408275212 series 2805304
المحتوى المقدم من Nutraceuticals World. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Nutraceuticals World أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

With rising interest in healthy aging, more people are looking for clinical research that supports products designed to help them live healthier for longer.
The coenzyme NAD+ is essential to the body's metabolic processes, but it declines with age, so supplements that boost NAD+ have garnered considerable attention in the scientific community.
ChromaDex, which is publicly traded on the Nasdaq, offers the consumer product brand Tru Niagen. This patented form of nicotinamide riboside (NR) is a precursor to NAD+.
Tru Niagen sales totaled nearly $70 million last year, accounting for the majority of the company’s $83.6 million in revenue.
In this interview, ChromaDex CEO Rob Fried discusses NAD+ and emerging research, the company’s evolution to become a consumer-focused nutraceutical, the future of aging, critical challenges in today’s dietary supplement market, and more.
Spoiler alert: Fried is calling for more accountability and collaboration to enforce quality standards and establish greater trust with consumers.
In addition to being CEO of ChromaDex since 2017 and the founder of Tru Niagen, Fried is an Academy Award and Emmy Award winning motion picture producer. Before his combined 7 years in the health industry, he held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President) and Fried Films (founder, CEO). He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research LLC.
In 2017, Fried led ChromaDex’s acquisition of Healthspan Research LLC, a consumer company offering Tru Niagen products, and raised funds with Horizon Ventures to offer Tru Niagen direct-to-consumer. He holds a BS from Cornell University and an MBA from the Columbia University Graduate School of Business.

  continue reading

24 حلقات

كل الحلقات

×
 
Loading …

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

 

دليل مرجعي سريع

استمع إلى هذا العرض أثناء الاستكشاف
تشغيل